ADVM — Adverum Biotechnologies Share News
0.000.00%
Last trade - 00:00- $94.05m
- $67.99m
- $1.00m
Adverum Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary
Adverum Biotechnologies Inc expected to post a loss of 31 cents a share - Earnings Preview
Adverum Biotechnologies Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Adverum Presents Additional Efficacy And Safety Data From Optic Trial Of ADVM-022 In Wet AMD
U.S. RESEARCH ROUNDUP- Biogen, FTC Solar, Palo Alto Networks
Brief: Adverum Biotechnologies Proceeds With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD After Receiving Requested Type C Meeting Feedback From FDA
Adverum Biotechnologies Inc reports results for the quarter ended in December - Earnings Summary
Adverum Biotechnologies Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Adverum Biotechnologies Reports Fourth Quarter And Full Year 2021 Financial Results
Adverum Biotechnologies Inc expected to post a loss of 34 cents a share - Earnings Preview
Adverum Biotechnologies Inc expected to post a loss of 34cents a share - Earnings Preview
Brief: Adverum Biotechnologies Increases Size Of Board To Nine Members
Adverum Biotechnologies Inc expected to post a loss of 34 cents a share - Earnings Preview
Adverum Biotechnologies Inc expected to post a loss of 34 cents a share - Earnings Preview
Adverum Biotechnologies Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Adverum Biotechnologies Granted Orphan Drug Designation By FDA For Gene Therapy Candidate In Preclinical Development For The Treatment Of Blue Cone Monochromacy
Brief: Adverum Biotechnologies Board Decreased Total Number Of Authorized Directors From Nine To Seven Directors
Brief: Adverum Biotechnologies Inc Finalizing Two-Dose Study Design For Phase 2 Trial Of ADVM-022 In Wet Amdwith Intention To Dose First Patient In Q32022
Brief: Adverum Biotechnologies Appoints Rupert D’Souza As CFO